chlorthalidone has been researched along with Cardiovascular Diseases in 52 studies
Chlorthalidone: A benzenesulfonamide-phthalimidine that tautomerizes to a BENZOPHENONES form. It is considered a thiazide-like diuretic.
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Whether chlorthalidone is superior to hydrochlorothiazide for preventing major adverse cardiovascular events in patients with hypertension is unclear." | 9.51 | Chlorthalidone vs. Hydrochlorothiazide for Hypertension-Cardiovascular Events. ( Brophy, MT; Cushman, WC; Ferguson, RE; Fiore, LD; Glassman, PA; Hau, C; Huang, GD; Ishani, A; Klint, A; Leatherman, SM; Lew, RA; Taylor, AA; Woods, P, 2022) |
| "In the Systolic Hypertension in the Elderly Program (SHEP) trial, conducted between 1985 and 1990, antihypertensive therapy with chlorthalidone-based stepped-care therapy resulted in a lower rate of cardiovascular events than placebo but effects on mortality were not significant." | 9.15 | Association between chlorthalidone treatment of systolic hypertension and long-term survival. ( Cabrera, J; Cheng, JQ; Cosgrove, NM; Davis, BR; Deng, Y; Kostis, JB; Pressel, SL, 2011) |
| " The authors studied the effects of these two classes of hypertension medications (doxazosin, an a blocker, and chlorthalidone, a diuretic) on cardiovascular disease outcomes in adults aged >55 years with hypertension and glucose disorders who were participants in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (8749 had known diabetes mellitus and 1690 had a newly diagnosed glucose disorder [fasting glucose >/=110 mg/dL])." | 9.11 | Cardiovascular outcomes using doxazosin vs. chlorthalidone for the treatment of hypertension in older adults with and without glucose disorders: a report from the ALLHAT study. ( Barzilay, JI; Basile, JN; Bettencourt, J; Black, H; Ciocon, JO; Davis, BR; Ellsworth, A; Force, RW; Goff, DC; Habib, G; Margolis, KL; Wiegmann, T, 2004) |
| "Serum uric acid independently predicts cardiovascular events in older persons with isolated systolic hypertension." | 9.09 | Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). ( Applegate, WB; Di Bari, M; Franse, LV; Pahor, M; Shorr, RI; Somes, GW; Wan, JY, 2000) |
| "The effect of atenolol and reserpine on incidence of strokes, coronary heart disease (CHD), cardiovascular disease (CVD), and mortality was assessed in 4736 persons aged 60 years and older with isolated systolic hypertension." | 9.08 | Effect of atenolol and reserpine on selected events in the systolic hypertension in the elderly program (SHEP). ( Berge, KG; Davis, BR; Hawkins, CM; Kostis, JB; Probstfield, J, 1995) |
| " Safety and tolerability evaluations were based on adverse events, ECG and laboratory tests, and clinically relevant reports of abnormalities." | 6.73 | Antihypertensive efficacy and safety of manidipine versus amlodipine in elderly subjects with isolated systolic hypertension: MAISH study. ( Alberici, M; Lembo, G; Payeras, AC; Sladek, K, 2007) |
| "Whether chlorthalidone is superior to hydrochlorothiazide for preventing major adverse cardiovascular events in patients with hypertension is unclear." | 5.51 | Chlorthalidone vs. Hydrochlorothiazide for Hypertension-Cardiovascular Events. ( Brophy, MT; Cushman, WC; Ferguson, RE; Fiore, LD; Glassman, PA; Hau, C; Huang, GD; Ishani, A; Klint, A; Leatherman, SM; Lew, RA; Taylor, AA; Woods, P, 2022) |
| "In this study, which titrated medications to a goal, participants assigned to chlorthalidone were less likely to develop treatment-resistant hypertension." | 5.24 | Treatment-Resistant Hypertension and Outcomes Based on Randomized Treatment Group in ALLHAT. ( Bangalore, S; Black, HR; Calhoun, DA; Cushman, WC; Davis, BR; Kostis, JB; Muntner, PM; Pressel, SL; Probstfield, JL; Rahman, M; Whelton, PK, 2017) |
| "We examined the effect of chlorthalidone-based stepped care on the competing risks of cardiovascular (CV) versus non-CV death in the Systolic Hypertension in the Elderly Program (SHEP)." | 5.19 | Competing cardiovascular and noncardiovascular risks and longevity in the systolic hypertension in the elderly program. ( Cabrera, J; Cheng, JQ; Cosgrove, NM; Davis, BR; Deng, Y; Kostis, JB; Kostis, WJ; Messerli, FH; Sedjro, JE; Swerdel, JN, 2014) |
| " We prospectively examined randomization to first-step chlorthalidone, a thiazide-type diuretic; amlodipine, a calcium-channel blocker; and lisinopril, an angiotensin-converting enzyme inhibitor, on BP control and cardiovascular outcomes in a hypertensive cohort stratified by baseline BMI [kg/m(2); normal weight (BMI <25), overweight (BMI = 25-29." | 5.19 | Blood pressure control and cardiovascular outcomes in normal-weight, overweight, and obese hypertensive patients treated with three different antihypertensives in ALLHAT. ( Barzilay, JI; Dart, RA; Davis, BR; Einhorn, PT; Graves, JW; Pressel, SL; Reisin, E; Retta, TM; Saklayen, MG; Yamal, JM, 2014) |
| "In the Systolic Hypertension in the Elderly Program (SHEP) trial, conducted between 1985 and 1990, antihypertensive therapy with chlorthalidone-based stepped-care therapy resulted in a lower rate of cardiovascular events than placebo but effects on mortality were not significant." | 5.15 | Association between chlorthalidone treatment of systolic hypertension and long-term survival. ( Cabrera, J; Cheng, JQ; Cosgrove, NM; Davis, BR; Deng, Y; Kostis, JB; Pressel, SL, 2011) |
| "To compare rates of coronary heart disease (CHD) and end-stage renal disease (ESRD) events; to determine whether glomerular filtration rate (GFR) independently predicts risk for CHD; and to report the efficacy of first-step treatment with a calcium-channel blocker (amlodipine) or an angiotensin-converting enzyme inhibitor (lisinopril), each compared with a diuretic (chlorthalidone), in modifying cardiovascular disease (CVD) outcomes in high-risk patients with hypertension stratified by GFR." | 5.12 | Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. ( Barzilay, J; Batuman, V; Davis, BR; Eckfeldt, JH; Farber, MA; Franklin, S; Henriquez, M; Kopyt, N; Louis, GT; Nwachuku, C; Pressel, S; Rahman, M; Saklayen, M; Stanford, C; Walworth, C; Ward, H; Whelton, PK; Wiegmann, T; Wright, JT, 2006) |
| " The authors studied the effects of these two classes of hypertension medications (doxazosin, an a blocker, and chlorthalidone, a diuretic) on cardiovascular disease outcomes in adults aged >55 years with hypertension and glucose disorders who were participants in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (8749 had known diabetes mellitus and 1690 had a newly diagnosed glucose disorder [fasting glucose >/=110 mg/dL])." | 5.11 | Cardiovascular outcomes using doxazosin vs. chlorthalidone for the treatment of hypertension in older adults with and without glucose disorders: a report from the ALLHAT study. ( Barzilay, JI; Basile, JN; Bettencourt, J; Black, H; Ciocon, JO; Davis, BR; Ellsworth, A; Force, RW; Goff, DC; Habib, G; Margolis, KL; Wiegmann, T, 2004) |
| "To compare the effect of doxazosin, an alpha-blocker, with chlorthalidone, a diuretic, on incidence of CVD in patients with hypertension as part of a study of 4 types of antihypertensive drugs: chlorthalidone, doxazosin, amlodipine, and lisinopril." | 5.09 | Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. ( , 2000) |
| "Serum uric acid independently predicts cardiovascular events in older persons with isolated systolic hypertension." | 5.09 | Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). ( Applegate, WB; Di Bari, M; Franse, LV; Pahor, M; Shorr, RI; Somes, GW; Wan, JY, 2000) |
| "The effect of atenolol and reserpine on incidence of strokes, coronary heart disease (CHD), cardiovascular disease (CVD), and mortality was assessed in 4736 persons aged 60 years and older with isolated systolic hypertension." | 5.08 | Effect of atenolol and reserpine on selected events in the systolic hypertension in the elderly program (SHEP). ( Berge, KG; Davis, BR; Hawkins, CM; Kostis, JB; Probstfield, J, 1995) |
| "Hydrochlorothiazide (HCTZ) is widely used for hypertension, and prescriptions for HCTZ outnumber those for chlorthalidone (CTDN) by >20-fold in 2 recent surveys." | 4.88 | Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses. ( Guddati, AK; Holford, TR; Roush, GC, 2012) |
| "Treatment with amlodipine, however, was not associated with a significant difference in conduction outcome events (HR, 0." | 2.82 | Effect of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) on Conduction System Disease. ( Albert, CM; Alonso, A; Davis, BR; Dewland, TA; Haywood, LJ; Magnani, JW; Marcus, GM; Piller, LB; Soliman, EZ; Yamal, JM, 2016) |
| "Hyperkalemia was associated with increased risk of combined cardiovascular disease (hazard ratio, 1." | 2.77 | Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. ( Alderman, MH; Calhoun, DA; Cushman, WC; Davis, BR; Eckfeldt, JH; Einhorn, PT; Ford, CE; Franklin, SS; Furberg, CD; Ong, ST; Oparil, S; Papademetriou, V; Piller, LB; Probstfield, JL, 2012) |
| " Safety and tolerability evaluations were based on adverse events, ECG and laboratory tests, and clinically relevant reports of abnormalities." | 2.73 | Antihypertensive efficacy and safety of manidipine versus amlodipine in elderly subjects with isolated systolic hypertension: MAISH study. ( Alberici, M; Lembo, G; Payeras, AC; Sladek, K, 2007) |
| "Angioedema is a rare, potentially life-threatening condition that has been associated with angiotensin-converting enzyme inhibitors since their introduction in the 1980s." | 2.72 | Incidence and predictors of angioedema in elderly hypertensive patients at high risk for cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ( Black, HR; Davis, BR; Ford, CE; Nwachuku, C; Oparil, S; Piller, LB; Probstfield, JL; Retta, TM, 2006) |
| " We sought to describe their comparative dose-response relationships for changes in systolic blood pressure (SBP) and potassium." | 2.46 | Meta-analysis of dose-response characteristics of hydrochlorothiazide and chlorthalidone: effects on systolic blood pressure and potassium. ( Carter, BL; Ernst, ME; Grimm, RH; Zheng, S, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (3.85) | 18.7374 |
| 1990's | 3 (5.77) | 18.2507 |
| 2000's | 23 (44.23) | 29.6817 |
| 2010's | 20 (38.46) | 24.3611 |
| 2020's | 4 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Itoga, NK | 1 |
| Tawfik, DS | 1 |
| Montez-Rath, ME | 1 |
| Chang, TI | 1 |
| Ishani, A | 2 |
| Cushman, WC | 7 |
| Leatherman, SM | 2 |
| Lew, RA | 2 |
| Woods, P | 2 |
| Glassman, PA | 2 |
| Taylor, AA | 2 |
| Hau, C | 2 |
| Klint, A | 2 |
| Huang, GD | 2 |
| Brophy, MT | 2 |
| Fiore, LD | 2 |
| Ferguson, RE | 2 |
| Liu, M | 1 |
| Higashi, K | 1 |
| Ueda, K | 1 |
| Moribe, K | 1 |
| Goldenberg, R | 1 |
| Bell, A | 1 |
| Cheng, W | 1 |
| Fils-Aimé, N | 1 |
| Burrows, M | 1 |
| Blavignac, J | 1 |
| Parron, E | 1 |
| Barakat, M | 1 |
| Dhruva, SS | 1 |
| Huang, C | 1 |
| Spatz, ES | 1 |
| Coppi, AC | 1 |
| Warner, F | 1 |
| Li, SX | 1 |
| Lin, H | 1 |
| Xu, X | 1 |
| Furberg, CD | 4 |
| Davis, BR | 19 |
| Pressel, SL | 7 |
| Coifman, RR | 1 |
| Krumholz, HM | 1 |
| Roush, GC | 2 |
| Buddharaju, V | 1 |
| Ernst, ME | 2 |
| Holford, TR | 2 |
| Kostis, JB | 5 |
| Sedjro, JE | 2 |
| Cabrera, J | 3 |
| Cosgrove, NM | 3 |
| Pantazopoulos, JS | 1 |
| Kostis, WJ | 2 |
| Messerli, FH | 1 |
| Cheng, JQ | 2 |
| Swerdel, JN | 1 |
| Deng, Y | 2 |
| Wang, JG | 1 |
| Yan, P | 1 |
| Jeffers, BW | 1 |
| Reisin, E | 1 |
| Graves, JW | 1 |
| Yamal, JM | 2 |
| Barzilay, JI | 3 |
| Einhorn, PT | 3 |
| Dart, RA | 1 |
| Retta, TM | 2 |
| Saklayen, MG | 1 |
| Thomopoulos, C | 1 |
| Parati, G | 1 |
| Zanchetti, A | 1 |
| Holzgreve, H | 1 |
| Dewland, TA | 1 |
| Soliman, EZ | 1 |
| Magnani, JW | 1 |
| Piller, LB | 4 |
| Haywood, LJ | 2 |
| Alonso, A | 1 |
| Albert, CM | 1 |
| Marcus, GM | 1 |
| Bangalore, S | 1 |
| Muntner, PM | 1 |
| Calhoun, DA | 3 |
| Whelton, PK | 4 |
| Probstfield, JL | 4 |
| Rahman, M | 2 |
| Black, HR | 3 |
| Czarina Acelajado, M | 1 |
| Carter, BL | 1 |
| Zheng, S | 1 |
| Grimm, RH | 1 |
| Cutler, JA | 4 |
| Ford, CE | 8 |
| Margolis, KL | 3 |
| Moloo, J | 1 |
| Oparil, S | 3 |
| Simmons, DL | 1 |
| Sweeney, ME | 1 |
| Wong, ND | 1 |
| Wright, JT | 3 |
| Alderman, MH | 2 |
| Franklin, SS | 2 |
| Papademetriou, V | 2 |
| Ong, ST | 1 |
| Eckfeldt, JH | 5 |
| Zhang, X | 1 |
| Lynch, AI | 2 |
| Boerwinkle, E | 3 |
| Leiendecker-Foster, C | 3 |
| Arnett, DK | 3 |
| Coca, S | 1 |
| Guddati, AK | 1 |
| Proschan, M | 1 |
| Graumlich, JF | 1 |
| Pavlik, V | 1 |
| Gordon, D | 1 |
| Blumenthal, SS | 1 |
| Castaldo, RS | 1 |
| Preston, RA | 1 |
| Tziomalos, K | 1 |
| Athyros, VG | 1 |
| Mikhailidis, DP | 1 |
| Karagiannis, A | 1 |
| Nilsson, P | 1 |
| Mancia, G | 1 |
| Rollins, G | 1 |
| GHIRON, G | 1 |
| AVOGADRO, L | 1 |
| Rahn, KH | 1 |
| Witham, MD | 1 |
| Davies, JI | 1 |
| Dawson, A | 1 |
| Davey, PG | 1 |
| Struthers, AD | 1 |
| Bettencourt, J | 1 |
| Goff, DC | 1 |
| Black, H | 3 |
| Habib, G | 1 |
| Ellsworth, A | 1 |
| Force, RW | 1 |
| Wiegmann, T | 2 |
| Ciocon, JO | 1 |
| Basile, JN | 1 |
| Ménard, J | 1 |
| Dunn, JK | 1 |
| Leenen, FH | 1 |
| Habib, GB | 1 |
| Miller, MB | 1 |
| Pressel, S | 1 |
| Nwachuku, C | 2 |
| Barzilay, J | 1 |
| Batuman, V | 1 |
| Farber, MA | 1 |
| Franklin, S | 1 |
| Henriquez, M | 1 |
| Kopyt, N | 1 |
| Louis, GT | 1 |
| Saklayen, M | 1 |
| Stanford, C | 1 |
| Walworth, C | 1 |
| Ward, H | 1 |
| Salvetti, A | 1 |
| Ghiadoni, L | 1 |
| Yusuf, S | 1 |
| Payeras, AC | 1 |
| Sladek, K | 1 |
| Lembo, G | 1 |
| Alberici, M | 1 |
| Kaplan, NM | 1 |
| Curb, JD | 1 |
| Savage, PJ | 1 |
| Applegate, WB | 2 |
| Camel, G | 1 |
| Frost, PH | 1 |
| Gonzalez, N | 1 |
| Guthrie, G | 1 |
| Oberman, A | 2 |
| Rutan, GH | 1 |
| Stamler, J | 1 |
| Berge, KG | 1 |
| Hawkins, CM | 1 |
| Probstfield, J | 1 |
| Lasagna, L | 1 |
| Koval, PG | 1 |
| McDiarmid, T | 1 |
| Franse, LV | 1 |
| Pahor, M | 1 |
| Di Bari, M | 1 |
| Shorr, RI | 1 |
| Wan, JY | 1 |
| Somes, GW | 1 |
| Wassertheil-Smoller, S | 1 |
| Blaufox, MD | 1 |
| Davis, B | 1 |
| Langford, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| CSP #597 - Diuretic Comparison Project[NCT02185417] | Phase 3 | 13,523 participants (Actual) | Interventional | 2016-06-15 | Completed | ||
| Short - Medium and Long Term Blood Pressure Variability in Essential Hypertensive Patients Treated With Nifedipine GITS or Ramipril - a Randomized Trial[NCT02499822] | Phase 4 | 168 participants (Actual) | Interventional | 2015-10-31 | Completed | ||
| [NCT00000542] | Phase 3 | 0 participants | Interventional | 1993-08-31 | Completed | ||
| Pharmacological Association of the Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism on Blood Pressure and Cardiovascular Risk in Relation to Anti-hypertensive Treatment[NCT00006294] | 37,939 participants (Actual) | Observational | 1999-09-30 | Completed | |||
| Evaluation of a Primary Treatment Algorithm Using Fixed Dose Combination Therapy for the Management of Hypertension - Control and Intervention Arms[NCT00129909] | Phase 4 | 2,081 participants (Actual) | Interventional | 2005-05-31 | Completed | ||
| Resistant Hypertension On Treatment - Sequential Nephron Blockade Compared to Dual Blockade of the Renin-angiotensin-aldosterone System Plus Bisoprolol in the Treatment of Resistant Arterial Hypertension: A Randomized Trial (ResHypOT)[NCT02832973] | Phase 4 | 72 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
| Pilot Study to Assess Blockade of Calcium Channels and Sodium Chloride Cotransporters for Physiologic Abnormalities in Liver Transplant Associated Hypertension[NCT05275907] | Phase 4 | 0 participants (Actual) | Interventional | 2022-07-12 | Withdrawn (stopped due to Screened participants did not meet inclusion criteria prior to study completion date) | ||
| A Pivotal Study To Evaluate The Effectiveness of Isometric Handgrip Therapy In Prehypertensive And Hypertensive Patients[NCT04467879] | 146 participants (Actual) | Interventional | 2020-06-01 | Terminated (stopped due to New Protocol and Outcome Measures in Review) | |||
| The Randomized Elimination or Prolongation of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Coronavirus Disease 2019[NCT04338009] | 152 participants (Actual) | Interventional | 2020-03-31 | Completed | |||
| GenHAT - Genetics of Hypertension Associated Treatments - Ancillary to ALLHAT[NCT00563901] | 37,939 participants (Actual) | Observational | 2000-09-30 | Completed | |||
| [NCT00000514] | Phase 3 | 0 participants | Interventional | 1984-06-30 | Completed | ||
| Improving Hypertension Control in Individuals With Diabetes[NCT00743808] | 11,510 participants (Actual) | Observational | 2006-12-31 | Completed | |||
| [NCT00000513] | Phase 3 | 0 participants | Interventional | 1984-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT04338009)
Timeframe: Up to 28 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Discontinuation Arm | 10 |
| Continuation Arm | 11 |
"The Area Under the Curve of the modified SOFA (AUC SOFA) from daily measurements, weighted to account for the shorter observation period among patients who die in-hospital.~How to interpret the AUC SOFA?: a higher area indicates more severe disease and/or longer hospitalization.The range is 0.1 to 377.3." (NCT04338009)
Timeframe: Up to 28 days
| Intervention | units on a scale (SOFA x days) (Median) |
|---|---|
| Discontinuation Arm | 7 |
| Continuation Arm | 12 |
"The primary endpoint of the trial will be a global rank based on patient outcomes according to four factors: (1) time to death, (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO), (3) the number of days supported by renal replacement therapy or pressor/inotropic therapy, and (4) a modified sequential Organ Failure Assessment (SOFA) score. The modified SOFA score will include the cardiac, respiratory, renal and coagulation domains of the SOFA score.~How to interpret the rank?: patients are ranked from worst to best outcomes, such that patients with bad outcomes are ranked at the top and patients who have the best outcomes are ranked at the bottom." (NCT04338009)
Timeframe: Up to 28 days
| Intervention | score on a scale (range 1 to 152) (Median) |
|---|---|
| Discontinuation Arm | 81 |
| Continuation Arm | 73 |
Hypotension Requiring Vasopressors, inotropes or mechanical hemodynamic support (ventricular assist device or intra-aortic balloon pump). (NCT04338009)
Timeframe: Up to 28 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Discontinuation Arm | 8 |
| Continuation Arm | 9 |
Need to be transferred to an intensive care unit or to supported by a breathing machine (NCT04338009)
Timeframe: Up to 28 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Discontinuation Arm | 14 |
| Continuation Arm | 16 |
This outcome measurement looked at the median length of hospitalization. (NCT04338009)
Timeframe: Up to 28 days
| Intervention | days (Median) |
|---|---|
| Discontinuation Arm | 5 |
| Continuation Arm | 6 |
(NCT04338009)
Timeframe: Up to 28 days
| Intervention | days (Median) |
|---|---|
| Discontinuation Arm | 15 |
| Continuation Arm | 13 |
9 reviews available for chlorthalidone and Cardiovascular Diseases
| Article | Year |
|---|---|
Chlorthalidone: mechanisms of action and effect on cardiovascular events.
Topics: Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Chlorthalidone; Humans; Renin-Angi | 2013 |
Effects of amlodipine and other classes of antihypertensive drugs on long-term blood pressure variability: evidence from randomized controlled trials.
Topics: Amlodipine; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Chlorthalido | 2014 |
Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs--overview and meta-analyses.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2015 |
Treatment of resistant hypertension.
Topics: Adrenal Gland Neoplasms; Adult; Aged; Ambulatory Care; Antihypertensive Agents; Black or African Ame | 2009 |
Meta-analysis of dose-response characteristics of hydrochlorothiazide and chlorthalidone: effects on systolic blood pressure and potassium.
Topics: Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Chlorthalidone; Clinical Trials as | 2010 |
Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Chlorthalidone; Humans; Hyd | 2012 |
Hydrochlorothiazide vs. chlorthalidone as the optimal diuretic for the management of hypertension.
Topics: Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Chlorthalidone; Diuretics; Humans; | 2013 |
[Recent intervention studies with antihypertensive drugs and their influence on guidelines].
Topics: Adrenergic beta-Antagonists; Aged; Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Convert | 2003 |
Thiazide diuretics in the treatment of hypertension: an update.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Clinical Trials as Topic; Glucose; | 2006 |
24 trials available for chlorthalidone and Cardiovascular Diseases
19 other studies available for chlorthalidone and Cardiovascular Diseases
| Article | Year |
|---|---|
Contributions of Systolic and Diastolic Blood Pressures to Cardiovascular Outcomes in the ALLHAT Study.
Topics: Aged; Amlodipine; Blood Pressure; Blood Pressure Determination; Cardiovascular Diseases; Chlorthalid | 2021 |
Supersaturation maintenance of carvedilol and chlorthalidone by cyclodextrin derivatives: Pronounced crystallization inhibition ability of methylated cyclodextrin.
Topics: Cardiovascular Diseases; Carvedilol; Chlorthalidone; Crystallization; Cyclodextrins; Humans; Solubil | 2023 |
Real-world effectiveness of treatments for type 2 diabetes, hypercholesterolemia, and hypertension in Canadian routine care - Results from the CardioVascular and metabolic treatment in Canada: Assessment of REal-life therapeutic value (CV-CARE) registry,
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Benzimidazoles; Canada; Cardiovascular Dise | 2020 |
Strengthening diuretics' role in hypertension.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Block | 2010 |
Life expectancy after treatment for systolic hypertension.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Female; Humans; Hypertension; Life | 2012 |
How much effect of different antihypertensive medications on cardiovascular outcomes is attributable to their effects on blood pressure?
Topics: Amlodipine; Antihypertensive Agents; Biostatistics; Blood Pressure; Cardiovascular Diseases; Chlorth | 2013 |
[ALLHAT--the most comprehensive antihypertensive treatment trial in the world. The significance of thiazide diuretics for patients older than 55 years is confirmed].
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzothiadiazin | 2003 |
[The ALLHAT study: contributions, limitations and prospectives].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; Cardiov | 2003 |
Diuretics are better first-line antihypertensive therapy than calcium channel blockers and ACE inhibitors.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Block | 2003 |
[CLINICAL CONTRIBUTION ON THE USE OF THE DIURETIC ASSOCIATION OF CHLORTHALIDONE-TRIAMTERENE].
Topics: Abdominal Neoplasms; Ascites; Biomedical Research; Cardiovascular Diseases; Chlorthalidone; Diuretic | 1964 |
Hypothetical economic analysis of screening for left ventricular hypertrophy in high-risk normotensive populations.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Cost-Benefit Analysis; Echocardiog | 2004 |
The 45-year story of the development of an anti-aldosterone more specific than spironolactone.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Clinical Trials as Topic; Erectile | 2004 |
Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Black People; C | 2005 |
Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Black People; C | 2005 |
Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Black People; C | 2005 |
Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Black People; C | 2005 |
Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Black People; C | 2005 |
Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Black People; C | 2005 |
Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Black People; C | 2005 |
Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Black People; C | 2005 |
Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Black People; C | 2005 |
Summaries for patients. Do the effects of blood pressure drugs differ by kidney function?
Topics: Aged; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Chronic Disease; | 2006 |
Preventing vascular events due to elevated blood pressure.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Comorbidity; Doxazosin; Drug Thera | 2006 |
Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertension.
Topics: Aged; Amlodipine; Antihypertensive Agents; Atrial Natriuretic Factor; Blood Pressure; Cardiovascular | 2008 |
Diuretics vs alpha-blockers for treatment of hypertension: lessons from ALLHAT. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Diur | 2000 |
How effective is doxazosin compared with chlorthalidone in the treatment of hypertension?
Topics: Aged; Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Coronary Disease; Diuretics; | 2000 |
Doxazosin, an inferior antihypertensive agent?
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Cont | 2002 |